Clinical trials: Tremor Essential
Essential Tremor
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead in Period followed by an Extension Open-label (OL)…
- Trial name
- Essential1 (NCT05021991)
- Testing
- 100 mg PRAX-944, 60 mg PRAX-944, Flexibly dosed 20 mg to 100 mg PRAX-944
- Where
- 39 sites in United States, Canada
- Volunteers
- 133 people
- Sponsor
- Praxis Precision Medicines
Essential Tremor, Parkinson's Disease
Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS)…
- Trial name
- EVIDENT (NCT03794661)
- Testing
- Clinician programmer electrode screening mode tool
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Abbott Medical Devices
Essential Tremor
Adaptive Portable Essential Tremor Monitor
The purpose of this study is to evaluate the utility of a portable motion sensor-based system designed to monitor essential tremor (ET) to better prescribe therapy to minimize symptoms and expand care for ET patients.
- Trial name
- NCT01602042
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Movement Disorders, Essential Tremor
ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of…
- Conditions
- Movement Disorders, Essential Tremor, Holmes Tremor, Parkinson's Disease
- Trial name
- NCT02252380
- Testing
- Transcranial ExAblate System
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Upper Limb Essential Tremor (UL ET)
Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating, and patients also experience associated…
- Trial name
- NCT05216250
- Testing
- BOTOX
- Where
- 40 sites in United States, Canada
- Volunteers
- 174 people
- Sponsor
- AbbVie
Parkinsonian Syndromes
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less…
- Trial name
- POET-2 (NCT00724906)
- Testing
- 123 I - ALTROPANE®
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Alseres Pharmaceuticals, Inc
Essential Tremor
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
The main objective of this study is to evaluate the efficacy, safety, and tolerability of NBI-827104 in adults with essential tremor.
- Trial name
- NCT04880616
- Testing
- NBI-827104
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- Neurocrine Biosciences
Essential Tremor
Prospective Study for Symptomatic Relief of ET With Cala Therapy
Prospective, multi-center, single-arm, non-significant risk study designed to evaluate the Cala TWO device. Subjects will be screened for eligibility and fitted with a Cala TWO device.
- Trial name
- PROSPECT (NCT03597100)
- Testing
- Cala TWO
- Where
- 32 sites in United States
- Volunteers
- 263 people
- Sponsor
- Cala Health, Inc.
Parkinson's Disease, Essential Tremor
Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation (DBS) Leads
The purpose of this study is to provide proof-of-concept that directional stimulation, in an intraoperative setting, is perceivable in a subject and is different from omnidirectional stimulation.
- Trial name
- NCT01764815
- Testing
- directSTN Acute lead connected to external neurostimulator
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Aleva Neurotherapeutics SA
Parkinson's Disease, Essential Tremor
Evaluation of Directional Recording and Stimulation Using spiderSTN
The purpose of this study is to provide proof-of-concept that directional stimulation and directional recording, in an intraoperative setting, is perceivable in a subject.
- Trial name
- NCT02894567
- Testing
- Intraoperative test during a deep brain stimulation surgery
- Where
- Switzerland
- Volunteers
- 6 people
- Sponsor
- Aleva Neurotherapeutics SA
Essential Tremor
A Pilot Study of the Cala ONE Device for Essential Tremor
Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no…
- Trial name
- EXCITE (NCT03152136)
- Testing
- Cala ONE device
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Cala Health, Inc.
Essential Tremor
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug.
- Trial name
- NCT01332695
- Testing
- ST101
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sonexa Therapeutics, Inc.